E-Newsletter - September 2022
Alliance Leadership News
Alliance LEADERSHIP TRANSITION: SUZANNE GEORGE, MD, APPOINTED INTERIM GROUP CHAIR
Suzanne George, MD, a leading medical oncologist and expert in sarcoma management and clinical investigation, has been appointed Interim Group Chair of the Alliance for Clinical Trials in Oncology. An Associate Professor of Medicine at Harvard Medical School and Clinical Director at the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute, Dr. George has served as Alliance Group Vice Chair since 2015 and succeeds Monica M. Bertagnolli, MD. Dr. Bertganolli, who served as Alliance Group Chair from 2011-2022, was recently appointed to serve as President Joe Biden’s pick for Director of the National Cancer Institute.
“I am so proud of the incredible Alliance team,” Dr. Bertagnolli said. “The Group's future is brighter than ever, as there is no lack of talented leadership ready at all levels to smoothly manage a Group Chair transition.”
Dr. George's areas of expertise include soft tissue sarcoma, bone sarcomas, and gastrointestinal stromal tumor (GIST). She has developed and led multiple clinical trials evaluating novel therapeutics for patients with advanced sarcomas and GIST, much of which has impacted the standard of care for patients with these diseases. She has also led one of the largest clinical multidisciplinary sarcoma teams, bringing together medical, surgical, radiation and orthopedic oncologists with the goal of optimizing patient care and outcomes.
In addition to her role as Interim Group Chair, Dr. George will serve as President of the Alliance for Clinical Trials in Oncology Foundation, Alliance NCTN Foundation, Alliance Foundation Trials, LLC, and Alliance Innovation DataLab. Olwen Hahn, MD, Principal Investigator and Director of the Alliance Central Protocol Operations Program, will serve alongside Dr. George as Vice President of the Alliance for Clinical Trials in Oncology Foundation, Alliance NCTN Foundation, Alliance Foundation Trials, LLC, and Alliance Innovation DataLab. Dr. Hahn is also an Associate Professor of Medicine in the Section of Hematology-Oncology at the University of Chicago.
The Alliance Group Chair election, which will be conducted by the Alliance Board of Directors, is proposed for May 2023.
Read more articles in this month's e-newsletter:
- Alliance Leadership Transition: Suzanne George, MD, Appointed Interim Group Chair
- Alliance Welcomes Three New Patient Advocates
-
October is National Breast Cancer Awareness Month
A011801 (COMPASS HER2 RD/Breast Cancer)
A071701 (Genomically-guided Treatment in Brain Metastases)
A191901 (Optimizing Endocrine Therapy)
A221803 (Reducing Radiation Dermatitis)
A231910CD (Patient-centered Communication in Breast Cancer) -
Spotlight on Alliance Trials
*Recently Activated Trials
A212102 (Multicancer Early Detection Blood Tests)
A032101 (Metastatic Hormone-sensitive Prostate Cancer)
*Ongoing Trials
A032002 (Metastatic Urothelial Cancer)
A051902 (Peripheral T-cell Lymphoma)
A081801 (Resected Non-small Cell Lung Cancer)
A222001 (Hot Flashes in Men/Androgen Deprivation Therapy) -
Announcements
Registration Now Open: 2022 Alliance Fall Hybrid Group Meeting
Call for Applications: Alliance CRP Committee Cadre Members
Call for Proposals: Alliance Cancer Control Program Pilot Awards -
Alliance in the News
Alliance for Clinical Trials in Oncology Applauds Appointment of Monica M. Bertagnolli as NCI's New Director
Interview with Patient on Alliance RadiCaL Study (A031801)
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Novel Drug Delivery Systems for Patients With Advanced Prostate Cancer: A Focus on Radioligand Therapy and ADCs
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated with Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)
Preoperative Combination Chemotherapy Improved Survival in Patients with Pancreatic Cancer
Alliance Foundation Trials Study Finds Combination Hormonal Therapy Delivered in Finite Period Improves PSA Levels in Patients with Prostate Cancer
Alliance MCED Biobank Study May Provide Greater Understanding of How to Detect Multiple Cancers